Recombinant Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810)
![Western blot - Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810)](https://www.abcam.com/ps/products/179/ab179810/Images/ab179810-384511-anti-loxl2-antibody-epr12733-c-terminal-western-blot-hela.jpg "Western blot - Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810)")
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR12733] to LOXL2 - C-terminal
- Suitable for: WB
- Knockout validated
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-LOXL2 antibody [EPR12733] - C-terminal
See all LOXL2 primary antibodies -
Description
Rabbit monoclonal [EPR12733] to LOXL2 - C-terminal -
Host species
Rabbit -
Specificity
Our lab has been unable to use this product successfully in IHC-P and so we cannot guarantee that it will work in this application. However, some customers have been successful with this antibody in IHC-P. -
Tested applications
Suitable for: WBmore details
Unsuitable for: IP -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat
-
Immunogen
Synthetic peptide within Human LOXL2 aa 750 to the C-terminus (C terminal) (Cysteine residue). The exact sequence is proprietary.
Database link: Q9Y4K0 -
Positive control
- WB: MDA-MB-435, A431, U87-MG, and HeLa cell lysates.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.5% BSA -
Concentration information loading... -
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR12733 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
KO cell lines
-
KO cell lysates
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab179810 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB | (1) |
1/200 - 1/1000. Predicted molecular weight: 87 kDa.
|
| Notes |
|---|
|
WB
1/200 - 1/1000. Predicted molecular weight: 87 kDa. |
Target
-
Tissue specificity
Expressed in many tissues. Highest expression in reproductive tissues, placenta, uterus and prostate. -
Sequence similarities
Belongs to the lysyl oxidase family.
Contains 4 SRCR domains. -
Post-translational
modificationsThe lysine tyrosylquinone cross-link (LTQ) is generated by condensation of the epsilon-amino group of a lysine with a topaquinone produced by oxidation of tyrosine. -
Cellular localization
Secreted > extracellular space. - Information by UniProt
-
Database links
- Entrez Gene: 4017 Human
- Entrez Gene: 94352 Mouse
- Entrez Gene: 290350 Rat
- Omim: 606663 Human
- SwissProt: Q9Y4K0 Human
- SwissProt: P58022 Mouse
- SwissProt: B5DF27 Rat
- Unigene: 626637 Human
see all -
Alternative names
- LOR 2 antibody
- LOR2 antibody
- LOX L2 antibody
see all
Images
-
Western blot - Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810)All lanes : Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810) at 1/500 dilution
Lane 1 : Wild-type HeLa cell lysate
Lane 2 : LOXL2 knockout HeLa cell lysate
Lane 3 : HeLa treated with 0.5nM CoCl2 for 6 hours whole cell lysate
Lane 4 : Untreated HeLa cell lysate
Lysates/proteins at 20 µg per lane.
Performed under reducing conditions.
Predicted band size: 87 kDa
Observed band size: 105 kDa why is the actual band size different from the predicted?Lanes 1-4: Merged signal (red and green). Green - ab179810 observed at 105 kDa. Red - loading control, ab8245 observed at 37 kDa.
ab179810 Anti-LOXL2 antibody [EPR12733] - C-terminal was shown to specifically react with LOXL2 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab264807 (knockout cell lysate ab257166) was used. Wild-type and LOXL2 knockout samples were subjected to SDS-PAGE. ab179810 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 500 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 10000 dilution for 1 hour at room temperature before imaging.
-
![Western blot - Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810)](https://www.abcam.com/ps/products/179/ab179810/Images/ab179810-384459-anti-loxl2-antibody-epr12733-c-terminal-western-blot-hela-2.jpg)
Western blot - Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810)All lanes : Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810) at 1/500 dilution
Lane 1 : Wild-type HeLa cell lysate
Lane 2 : LOXL2 knockout HeLa cell lysate
Lane 3 : HeLa treated with 0.5nM CoCl2 for 6 hours whole cell lysate
Lane 4 : Untreated HeLa cell lysate
Lysates/proteins at 20 µg per lane.
Performed under reducing conditions.
Predicted band size: 87 kDa
Observed band size: 105 kDa why is the actual band size different from the predicted?Lanes 1-4: Merged signal (red and green). Green - ab179810 observed at 105 kDa. Red - loading control, ab8245 observed at 37 kDa.
ab179810 Anti-LOXL2 antibody [EPR12733] - C-terminal was shown to specifically react with LOXL2 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab261804 (knockout cell lysate ab257168) was used. Wild-type and LOXL2 knockout samples were subjected to SDS-PAGE. ab179810 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 500 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (ab216776) secondary antibodies at 1 in 10000 dilution for 1 hour at room temperature before imaging.
-
![Western blot - Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810)](https://www.abcam.com/ps/products/179/ab179810/Images/ab179810-292543-anti-loxl2-antibody-epr12733-c-terminal-western-blot.jpg)
Western blot - Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810)Lanes 1-2 & 4 : Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810) at 1/1000 dilution
Lane 3 : Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810) at 1/200 dilution
Lane 1 : MCF-7 (Human breast carcinoma) whole cell lysate
Lane 2 : MDA-MB-435 (Human ductal carcinoma) whole cell lysate
Lane 3 : A431 (Human epidermoid carcinoma) whole cell lysate
Lane 4 : U87-MG (Human glioblastoma) whole cell lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 87 kDa
Observed band size: 105 kDa why is the actual band size different from the predicted?Exposure time:
Lane 1-3: 3min
Lane 4: 1minBlocking/Diluting buffer and concentration 5% NFDM /TBST
MCF-7 lack LOXL2 expression (PMID: 19330836, PMID:12154058 and PMID: 27655685)
-
![Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810)](https://www.abcam.com/ps/products/179/ab179810/Images/ab179810-9-benefits-of-recombinant-antibodies.png)
Anti-LOXL2 antibody [EPR12733] - C-terminal (ab179810)
Protocols
Datasheets and documents
-
Datasheet download
References (10)
ab179810 has been referenced in 10 publications.
- Wen L et al. Phenylethanol glycosides from Herba Cistanche improve the hypoxic tumor microenvironment and enhance the effects of oxaliplatin via the HIF-1a signaling pathway. Mol Med Rep 24:N/A (2021). PubMed: 34013363
- Klepfish M et al. LOXL2 Inhibition Paves the Way for Macrophage-Mediated Collagen Degradation in Liver Fibrosis. Front Immunol 11:480 (2020). PubMed: 32296422
- Fan Z et al. LOXL2 upregulates hypoxia-inducible factor-1a signaling through Snail-FBP1 axis in hepatocellular carcinoma cells. Oncol Rep 43:1641-1649 (2020). PubMed: 32323822
- Peng T et al. The interaction of LOXL2 with GATA6 induces VEGFA expression and angiogenesis in cholangiocarcinoma. Int J Oncol 55:657-670 (2019). PubMed: 31322171
- Hong X & Yu JJ Silencing of lysyl oxidase-like 2 inhibits the migration, invasion and epithelial-to-mesenchymal transition of renal cell carcinoma cells through the Src/FAK signaling pathway. Int J Oncol 54:1676-1690 (2019). PubMed: 30816490
- Craighead DH et al. Acute lysyl oxidase inhibition alters microvascular function in normotensive but not hypertensive men and women. Am J Physiol Heart Circ Physiol 314:H424-H433 (2018). PubMed: 29167120
- Cui X et al. Lysyl oxidase-like 2 is highly expressed in colorectal cancer cells and promotes the development of colorectal cancer. Oncol Rep 40:932-942 (2018). PubMed: 29845296
- Mižíková I et al. Perturbations to lysyl oxidase expression broadly influence the transcriptome of lung fibroblasts. Physiol Genomics 49:416-429 (2017). PubMed: 28698228
- Zhan XH et al. A three-gene signature from protein-protein interaction network of LOXL2- and actin-related proteins for esophageal squamous cell carcinoma prognosis. Cancer Med 6:1707-1719 (2017). PubMed: 28556501
- Wu L et al. The effect of LOXL2 in hepatocellular carcinoma. Mol Med Rep 14:1923-32 (2016). IHC-P ; Human . PubMed: 27430160
